Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-cetuximab PET uptake study in metastatic colorectal cancer
NL-OMON36409Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Jan 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of cetuximab in colorectal cancer (CRC), sponsored by Vrije University Medical Center. Primary endpoints: Detection of 89Zr-cetuximab uptake in non-hepatic tumor lesions and Association of non-hepatic tumor uptake with treatment outcome. Started Jan 2012; status: active, not recruiting.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON36409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36409.